Journal
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Volume -, Issue -, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/ijgc-2023-004739
Keywords
Endometrial Neoplasms
Categories
Ask authors/readers for more resources
This article discusses the potential of combining CDK4/6 inhibitors with hormonal therapy as an important addition to the first-line treatment options for patients with low-grade advanced or recurrent endometrial cancer.
Metastatic or recurrent endometrioid adenocarcinoma of the uterine corpus is often incurable with limited treatment options. First-line treatment often includes cytotoxic chemotherapy, which incurs significant toxicities for many patients. Endometrial cancer, specifically endometrioid cancer, is a hormone-sensitive disease and, while single-agent hormonal therapies have demonstrated clinical benefit, resistance to these agents often leads to the use of chemotherapy. There is a lack of approved endocrine treatment options in the metastatic setting for most recurrent endometrial cancers, representing an unmet clinical need. Emerging evidence suggests that hormonal therapy in combination with other targeted treatments, such as cyclin dependent kinase (CDK)4/6 inhibitors, is well tolerated and effective in select patient populations. We discuss the clinical evidence suggesting that the combination of CDK4/6 inhibitors and hormonal therapy has the potential to represent an important addition to the first-line treatment options for patients with low-grade advanced or recurrent endometrial cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available